Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach

P Lagergren; P Fayers; T Conroy; HJ Stein; O Sezer; R Hardwick; E Hammerlid; A Bottomley; E Van Cutsem; JM Blazeby; Groups on behalf of the European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life

doi:10.1016/j.ejca.2007.07.005

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach

P Lagergren, P Fayers, T Conroy, HJ Stein, O Sezer, R Hardwick, E Hammerlid, A Bottomley, E Van Cutsem, JM Blazeby, Groups on behalf of the European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

149 Citations (Scopus)

Abstract

Aim To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach. Methods The QLQ-OES18, QLQ-STO22 and seven modified items were administered to 300 patients with oesophageal (n = 148), junctional (n = 66), or gastric cancer (n = 86). Semi-structured interviews assessed item and scale preference and multi-trait scaling analyses confirmed the scale structure of the new module (QLQ-OG25). This was further tested for validity. Results The QLQ-OG25 has six scales, dysphagia, eating restrictions, reflux, odynophagia, pain and anxiety. Scales have good reliability ([alpha] range 0.67-0.87) and they distinguish between tumour sites and disease stage. Scales do not correlate highly with scores from the core questionnaire, thus indicating that the module was addressing separate HRQL aspects. Conclusion The QLQ-OG25 is recommended to supplement the EORTC QLQ-C30 when assessing HRQL in patients with oesophageal, junctional or gastric cancer.

Translated title of the contribution	Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach
Original language	English
Pages (from-to)	2066 - 2073
Number of pages	8
Journal	European Journal of Cancer
Volume	43 (14)
DOIs	https://doi.org/10.1016/j.ejca.2007.07.005
Publication status	Published - Sept 2007

Bibliographical note

Publisher: Elsevier
Other identifier: PMID: 17702567

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2007.07.005

http://dx.doi.org/10.1016/j.ejca.2007.07.005

Handle.net

Persistent link

Fingerprint

Dive into the research topics of 'Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach'. Together they form a unique fingerprint.

Cite this

Lagergren, P., Fayers, P., Conroy, T., Stein, HJ., Sezer, O., Hardwick, R., Hammerlid, E., Bottomley, A., Van Cutsem, E., Blazeby, JM., & on behalf of the European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life, G. (2007). Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. European Journal of Cancer, 43 (14), 2066 - 2073. https://doi.org/10.1016/j.ejca.2007.07.005

@article{22c9096294674df495ed288dc4fa8a2c,

title = "Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach",

abstract = "Aim To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach. Methods The QLQ-OES18, QLQ-STO22 and seven modified items were administered to 300 patients with oesophageal (n = 148), junctional (n = 66), or gastric cancer (n = 86). Semi-structured interviews assessed item and scale preference and multi-trait scaling analyses confirmed the scale structure of the new module (QLQ-OG25). This was further tested for validity. Results The QLQ-OG25 has six scales, dysphagia, eating restrictions, reflux, odynophagia, pain and anxiety. Scales have good reliability ([alpha] range 0.67-0.87) and they distinguish between tumour sites and disease stage. Scales do not correlate highly with scores from the core questionnaire, thus indicating that the module was addressing separate HRQL aspects. Conclusion The QLQ-OG25 is recommended to supplement the EORTC QLQ-C30 when assessing HRQL in patients with oesophageal, junctional or gastric cancer.",

author = "P Lagergren and P Fayers and T Conroy and HJ Stein and O Sezer and R Hardwick and E Hammerlid and A Bottomley and {Van Cutsem}, E and JM Blazeby and {on behalf of the European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life}, Groups",

note = "Publisher: Elsevier Other identifier: PMID: 17702567 ",

year = "2007",

month = sep,

doi = "10.1016/j.ejca.2007.07.005",

language = "English",

volume = "43 (14)",

pages = "2066 -- 2073",

journal = "European Journal of Cancer",

issn = "1879-0852",

publisher = "European School of Oncology (ESO)",

}

Lagergren, P, Fayers, P, Conroy, T, Stein, HJ, Sezer, O, Hardwick, R, Hammerlid, E, Bottomley, A, Van Cutsem, E, Blazeby, JM & on behalf of the European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life, G 2007, 'Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach', European Journal of Cancer, vol. 43 (14), pp. 2066 - 2073. https://doi.org/10.1016/j.ejca.2007.07.005

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. / Lagergren, P; Fayers, P; Conroy, T et al.
In: European Journal of Cancer, Vol. 43 (14), 09.2007, p. 2066 - 2073.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach

AU - Lagergren, P

AU - Fayers, P

AU - Conroy, T

AU - Stein, HJ

AU - Sezer, O

AU - Hardwick, R

AU - Hammerlid, E

AU - Bottomley, A

AU - Van Cutsem, E

AU - Blazeby, JM

AU - on behalf of the European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life, Groups

N1 - Publisher: Elsevier Other identifier: PMID: 17702567

PY - 2007/9

Y1 - 2007/9

N2 - Aim To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach. Methods The QLQ-OES18, QLQ-STO22 and seven modified items were administered to 300 patients with oesophageal (n = 148), junctional (n = 66), or gastric cancer (n = 86). Semi-structured interviews assessed item and scale preference and multi-trait scaling analyses confirmed the scale structure of the new module (QLQ-OG25). This was further tested for validity. Results The QLQ-OG25 has six scales, dysphagia, eating restrictions, reflux, odynophagia, pain and anxiety. Scales have good reliability ([alpha] range 0.67-0.87) and they distinguish between tumour sites and disease stage. Scales do not correlate highly with scores from the core questionnaire, thus indicating that the module was addressing separate HRQL aspects. Conclusion The QLQ-OG25 is recommended to supplement the EORTC QLQ-C30 when assessing HRQL in patients with oesophageal, junctional or gastric cancer.

AB - Aim To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach. Methods The QLQ-OES18, QLQ-STO22 and seven modified items were administered to 300 patients with oesophageal (n = 148), junctional (n = 66), or gastric cancer (n = 86). Semi-structured interviews assessed item and scale preference and multi-trait scaling analyses confirmed the scale structure of the new module (QLQ-OG25). This was further tested for validity. Results The QLQ-OG25 has six scales, dysphagia, eating restrictions, reflux, odynophagia, pain and anxiety. Scales have good reliability ([alpha] range 0.67-0.87) and they distinguish between tumour sites and disease stage. Scales do not correlate highly with scores from the core questionnaire, thus indicating that the module was addressing separate HRQL aspects. Conclusion The QLQ-OG25 is recommended to supplement the EORTC QLQ-C30 when assessing HRQL in patients with oesophageal, junctional or gastric cancer.

U2 - 10.1016/j.ejca.2007.07.005

DO - 10.1016/j.ejca.2007.07.005

M3 - Article (Academic Journal)

C2 - 17702567

SN - 1879-0852

VL - 43 (14)

SP - 2066

EP - 2073

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. European Journal of Cancer. 2007 Sept;43 (14):2066 - 2073. doi: 10.1016/j.ejca.2007.07.005